Slingshot members are tracking this event:

Alere HIV Combo Test Receives WHO Prequalification

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Conventional second- and third-generation HIV rapid tests can only detect antibodies against HIV which may not appear until three weeks after infection. 1 Alere HIV Combo detects not only these antibodies but can also detect free HIV-1 p24 antigen which can appear up to 7.7 days earlier. 1 For global HIV programmes this means the potential to increase case finding particularly in key high risk populations that have been disproportionally affected by HIV.

“We can’t meet UNAIDS’ 90-90-90 target unless we achieve the first goal of ensuring that people with HIV know their status, and this requires helping healthcare workers in developing countries make every testing opportunity count,” said Collins Odhiambo, Ph.D., who evaluated the Alere HIV Combo at the Kenya Medical Research Institute (KEMRI). “The Alere HIV Combo brings point-of-care diagnosis directly to people at greatest risk for infection – including those in remote areas – and makes screenings as impactful as possible by enabling healthcare workers to identify highly infectious individuals, and link them to treatment.”
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 13, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Hiv Combo, Hiv-1 P24 Antigen